A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
Company profile
Ticker
EXAS
Exchange
Website
CEO
Kevin Conroy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
EXACT CORP
SEC CIK
Corporate docs
Subsidiaries
Genomic Health, Inc. • Exact Sciences Laboratories, LLC • Exact Sciences Thrive, LLC ...
IRS number
204782291
EXAS stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Other Events
17 Mar 23
424B7
Prospectus with selling stockholder info
17 Mar 23
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
3 Mar 23
8-K
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
1 Mar 23
10-K
2021 FY
Annual report
21 Feb 23
8-K
Exact Sciences Announces Fourth Quarter 2022 Results
21 Feb 23
8-K
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
9 Jan 23
8-K
Departure of Directors or Certain Officers
30 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
3 Nov 22
Transcripts
EXAS
Earnings call transcript
2022 Q4
21 Feb 23
EXAS
Earnings call transcript
2022 Q3
4 Nov 22
EXAS
Earnings call transcript
2022 Q2
2 Aug 22
EXAS
Earnings call transcript
2022 Q1
27 Apr 22
EXAS
Earnings call transcript
2021 Q4
23 Feb 22
EXAS
Earnings call transcript
2021 Q3
3 Nov 21
EXAS
Earnings call transcript
2021 Q2
29 Jul 21
EXAS
Earnings call transcript
2021 Q1
5 May 21
EXAS
Earnings call transcript
2020 Q4
17 Feb 21
EXAS
Earnings call transcript
2020 Q4
16 Feb 21
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 242.79 mm | 242.79 mm | 242.79 mm | 242.79 mm | 242.79 mm | 242.79 mm |
| Cash burn (monthly) | (no burn) | 6.08 mm | 43.31 mm | 52.71 mm | (no burn) | 18.63 mm |
| Cash used (since last report) | n/a | 16.36 mm | 116.53 mm | 141.84 mm | n/a | 50.13 mm |
| Cash remaining | n/a | 226.43 mm | 126.26 mm | 100.95 mm | n/a | 192.66 mm |
| Runway (months of cash) | n/a | 37.2 | 2.9 | 1.9 | n/a | 10.3 |
Institutional ownership, Q4 2022
93.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 533 |
| Opened positions | 125 |
| Closed positions | 57 |
| Increased positions | 160 |
| Reduced positions | 159 |
| 13F shares | Current |
|---|---|
| Total value | 7.97 tn |
| Total shares | 167.04 mm |
| Total puts | 2.00 mm |
| Total calls | 1.76 mm |
| Total put/call ratio | 1.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 17.25 mm | $854.17 bn |
| ARK Investment Management | 16.04 mm | $794.16 bn |
| BLK Blackrock | 11.35 mm | $562.16 bn |
| Wellington Management | 10.25 mm | $507.57 bn |
| JPM JPMorgan Chase & Co. | 7.75 mm | $384.33 bn |
| CMTDF Sumitomo Mitsui Trust | 5.36 mm | $265.60 bn |
| Capital World Investors | 5.19 mm | $257.03 bn |
| STT State Street | 5.18 mm | $256.40 bn |
| T. Rowe Price | 4.99 mm | $247.59 bn |
| Baillie Gifford & Co | 4.93 mm | $244.15 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Mar 23 | Jacob A Orville | Common Stock | Sell | Dispose S | No | Yes | 65 | 5,000 | 325.00 k | 11,423 |
| 1 Mar 23 | Sarah Condella | Common Stock | Sell | Dispose S | No | Yes | 62 | 1,000 | 62.00 k | 87,692 |
| 1 Mar 23 | Everett Cunningham | Common Stock | Sell | Dispose S | No | Yes | 62.01 | 3,628 | 224.97 k | 22,703 |
| 28 Feb 23 | Jeffrey Thomas Elliott | Common Stock | Sell | Dispose S | No | Yes | 61.12 | 4,233 | 258.72 k | 29,241 |
| 27 Feb 23 | Jeffrey Thomas Elliott | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,437 | 0.00 | 33,474 |
| 27 Feb 23 | Jeffrey Thomas Elliott | Common Stock | Option exercise | Acquire M | No | No | 0 | 5,700 | 0.00 | 30,037 |
| 27 Feb 23 | Jeffrey Thomas Elliott | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,437 | 0.00 | 0 |
| 27 Feb 23 | Jeffrey Thomas Elliott | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 5,700 | 0.00 | 17,102 |
| 27 Feb 23 | Everett Cunningham | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,677 | 0.00 | 26,331 |
| 27 Feb 23 | Everett Cunningham | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,677 | 0.00 | 23,034 |
News
Meta Platforms To Rally Over 36%? Here Are 10 Other Analyst Forecasts For Wednesday
15 Mar 23
Benchmark Maintains Buy on Exact Sciences, Raises Price Target to $78
15 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
9 Mar 23
Citigroup Upgrades Exact Sciences to Buy, Raises Price Target to $90
9 Mar 23
Analyst Ratings for Exact Sciences
3 Mar 23
Press releases
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
23 Feb 23
Exact Sciences to participate in March investor conferences
22 Feb 23
Exact Sciences Announces Fourth Quarter 2022 Results
21 Feb 23
Exact Sciences Launches OncoExTra™ Cancer Therapy Selection Test in the U.S.
7 Feb 23
Exact Sciences schedules fourth quarter 2022 earnings call
1 Feb 23